| Item Type | Name |
|
Academic Article
|
High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia.
|
|
Academic Article
|
Infections in patients with aplastic anemia: experience at a tertiary care cancer center.
|
|
Academic Article
|
Acute lymphoblastic leukemia following preleukemic syndromes in adults.
|
|
Concept
|
Anemia, Hemolytic, Autoimmune
|
|
Concept
|
Anemia, Refractory, with Excess of Blasts
|
|
Concept
|
Anemia, Refractory
|
|
Concept
|
Anemia, Myelophthisic
|
|
Concept
|
Anemia
|
|
Concept
|
Anemia, Sideroblastic
|
|
Concept
|
Anemia, Aplastic
|
|
Academic Article
|
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
|
|
Academic Article
|
Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
|
|
Academic Article
|
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.
|
|
Academic Article
|
Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
|
|
Academic Article
|
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia.
|
|
Academic Article
|
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
|
|
Academic Article
|
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
|
Academic Article
|
Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
|
|
Academic Article
|
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
|
|
Academic Article
|
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
|
|
Academic Article
|
A prognostic score for patients with lower risk myelodysplastic syndrome.
|
|
Academic Article
|
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
|
|
Academic Article
|
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
|
|
Academic Article
|
Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.
|
|
Academic Article
|
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine.
|
|
Academic Article
|
Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy.
|
|
Academic Article
|
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
|
|
Academic Article
|
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
|
|
Academic Article
|
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
|
|
Academic Article
|
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
|
|
Academic Article
|
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
|
|
Academic Article
|
Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
|
|
Academic Article
|
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
|
|
Academic Article
|
Current and future management options for myelodysplastic syndromes.
|
|
Academic Article
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
|
Academic Article
|
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
|
|
Academic Article
|
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
|
|
Academic Article
|
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
|
|
Academic Article
|
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
|
|
Academic Article
|
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
|
|
Academic Article
|
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
|
|
Academic Article
|
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.
|
|
Academic Article
|
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
|
Academic Article
|
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.
|
|
Academic Article
|
Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia.
|
|
Academic Article
|
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
|
|
Academic Article
|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
|
|
Academic Article
|
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
|
|
Academic Article
|
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
|
|
Academic Article
|
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
|
|
Academic Article
|
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
|
|
Academic Article
|
Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
|
|
Academic Article
|
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
|
|
Academic Article
|
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
|
|
Academic Article
|
Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
|
|
Academic Article
|
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
|